Johnson & Johnson (NYSE:JNJ) Holdings Lowered by Absher Wealth Management LLC

Absher Wealth Management LLC reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 7.9% in the 3rd quarter, Holdings Channel reports. The fund owned 190,588 shares of the company’s stock after selling 16,357 shares during the period. Johnson & Johnson makes up 4.0% of Absher Wealth Management LLC’s investment portfolio, making the stock its 8th largest position. Absher Wealth Management LLC’s holdings in Johnson & Johnson were worth $30,887,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of JNJ. Innealta Capital LLC purchased a new stake in Johnson & Johnson during the second quarter worth $27,000. Highline Wealth Partners LLC purchased a new stake in shares of Johnson & Johnson during the 3rd quarter worth about $31,000. Mowery & Schoenfeld Wealth Management LLC grew its position in shares of Johnson & Johnson by 58.7% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock valued at $40,000 after acquiring an additional 91 shares during the period. Morton Brown Family Wealth LLC increased its stake in shares of Johnson & Johnson by 400.0% in the 3rd quarter. Morton Brown Family Wealth LLC now owns 250 shares of the company’s stock valued at $41,000 after purchasing an additional 200 shares in the last quarter. Finally, MFA Wealth Advisors LLC acquired a new position in Johnson & Johnson in the 2nd quarter worth about $43,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on JNJ shares. Sanford C. Bernstein upped their target price on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Citigroup increased their price objective on shares of Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a report on Wednesday, October 16th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 16th. The Goldman Sachs Group lowered their price objective on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a report on Friday, July 19th. Finally, TD Cowen reduced their target price on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a report on Thursday, July 18th. Six analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $175.93.

Insider Buying and Selling at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the transaction, the vice president now directly owns 18,973 shares in the company, valued at approximately $3,131,683.38. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 0.2 %

Shares of NYSE:JNJ opened at $160.13 on Friday. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The business has a fifty day moving average of $163.31 and a two-hundred day moving average of $155.51. The stock has a market cap of $385.53 billion, a P/E ratio of 23.17, a PEG ratio of 2.84 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The company had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. During the same period in the previous year, the firm earned $2.66 earnings per share. Johnson & Johnson’s quarterly revenue was up 5.2% compared to the same quarter last year. On average, research analysts expect that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 annualized dividend and a yield of 3.10%. Johnson & Johnson’s dividend payout ratio (DPR) is 71.78%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.